Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Hypothalamic and brainstem glucose-dependent insulinotropic polypeptide receptor neurons employ distinct mechanisms to affect feeding
Alice Adriaenssens, … , Fiona Gribble, Frank Reimann
Alice Adriaenssens, … , Fiona Gribble, Frank Reimann
Published May 22, 2023
Citation Information: JCI Insight. 2023;8(10):e164921. https://doi.org/10.1172/jci.insight.164921.
View: Text | PDF
Research Article Metabolism Neuroscience

Hypothalamic and brainstem glucose-dependent insulinotropic polypeptide receptor neurons employ distinct mechanisms to affect feeding

  • Text
  • PDF
Abstract

Central glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) signaling is critical in GIP-based therapeutics’ ability to lower body weight, but pathways leveraged by GIPR pharmacology in the brain remain incompletely understood. We explored the role of Gipr neurons in the hypothalamus and dorsal vagal complex (DVC) — brain regions critical to the control of energy balance. Hypothalamic Gipr expression was not necessary for the synergistic effect of GIPR/GLP-1R coagonism on body weight. While chemogenetic stimulation of both hypothalamic and DVC Gipr neurons suppressed food intake, activation of DVC Gipr neurons reduced ambulatory activity and induced conditioned taste avoidance, while there was no effect of a short-acting GIPR agonist (GIPRA). Within the DVC, Gipr neurons of the nucleus tractus solitarius (NTS), but not the area postrema (AP), projected to distal brain regions and were transcriptomically distinct. Peripherally dosed fluorescent GIPRAs revealed that access was restricted to circumventricular organs in the CNS. These data demonstrate that Gipr neurons in the hypothalamus, AP, and NTS differ in their connectivity, transcriptomic profile, peripheral accessibility, and appetite-controlling mechanisms. These results highlight the heterogeneity of the central GIPR signaling axis and suggest that studies into the effects of GIP pharmacology on feeding behavior should consider the interplay of multiple regulatory pathways.

Authors

Alice Adriaenssens, Johannes Broichhagen, Anne de Bray, Julia Ast, Annie Hasib, Ben Jones, Alejandra Tomas, Natalie Figueredo Burgos, Orla Woodward, Jo Lewis, Elisabeth O’Flaherty, Kimberley El, Canqi Cui, Norio Harada, Nobuya Inagaki, Jonathan Campbell, Daniel Brierley, David J. Hodson, Ricardo Samms, Fiona Gribble, Frank Reimann

×

Figure 1

Hypothalamic Gipr expression is not necessary for GIPR/GLP-1R dual agonism–mediated weight loss.

Options: View larger image (or click on image) Download as PowerPoint
Hypothalamic Gipr expression is not necessary for GIPR/GLP-1R dual agoni...
(A) DIO GiprΔHyp and GiprWT Hyp mice were dosed with vehicle, GLP-140 (30 nmol/kg, s.c.), or GLP-140 (30 nmol/kg, s.c.) + GIP-085 (300 nmol/kg s.c.) for 12 days. (B) GiprΔSst and GiprWT mice were dosed with GLP-140 (30 nmol/kg, s.c.) + GIP-085 (300 nmol/kg s.c.) for 12 days. Daily body weight and food intake were measured throughout the study. Changes in body weight were calculated as a percentage of the body weight of the same animal prior to the first injection. Statistical comparisons made using a repeated measures 2-way ANOVA with a Sidak’s post hoc test. *P <0.05 GLP-140 versus GLP-140 + GIP-085 same genotype, $P <0.05 GLP-140 + GIP-085 in GiprΔHyp versus GiprWT Hyp, #P <0.05 GLP-140 in GiprΔHyp versus GiprWT Hyp; n = 5–11.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts